* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download TO DOWNLOAD OUR Mobic INFORMATION PACKAGE
Survey
Document related concepts
Psychopharmacology wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Compounding wikipedia , lookup
Pharmacognosy wikipedia , lookup
Neuropharmacology wikipedia , lookup
Drug design wikipedia , lookup
Drug discovery wikipedia , lookup
Drug interaction wikipedia , lookup
List of off-label promotion pharmaceutical settlements wikipedia , lookup
Prescription costs wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Theralizumab wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Discovery and development of cyclooxygenase 2 inhibitors wikipedia , lookup
Transcript
Parker & Waichman, LLP Attorneys at Law Mobic Information Guide The Case Against Mobic: Mobic has revealed a greater risk of heart attacks in early data than found with Merck & Co. Inc.'s now-withdrawn Vioxx, a veteran U.S. Food and Drug Administration scientist told an FDA advisory panel. Manufacturer: Boehringer Ingelheim Generic Name: Meloxicam Date Approved: April 14, 2000 Status: On the market Approved Uses: Adult osteoarthritis Serious Side Effects: Heart Attack Blood clots Stroke Related Topics: Bextra Celebrex Vioxx Cox- II Inhibitors Blood Clots Heart Attacks Stroke Defective Drugs Diseases The drug, made by privately-held Boehringer Ingelheim Pharmaceuticals, exhibited the effect in a new, yet-to-be published study, said David Graham, associate director for science and medicine at the FDA's Office of Drug Safety. "We found an increased risk," Graham said. "It's one study. It's the only study." Mobic has become the top-selling prescription pain drug since Merck pulled Vioxx, and any possible heart attack risk is important as more patients take the drug, Graham said. Graham, along with other scientists outside the FDA, analyzed data culled from California's Medicaid program of more than 15,000 heart attack patients, making it the largest study to date on such risks. They found the statistical risk of heart attack was 1.37 for Mobic, compared to 1.32 with Vioxx and 1.09 with Celebrex. Celebrex, Bextra and Vioxx, are part of a class called Cox-2 inhibitors, a newer type of non-steroidal anti-inflammatory drug (NSAID). Mobic is classified as a Cox-2 in some countries but is not considered part of that group in the United States, where it’s only classified as part of the larger NSAID class, a Boehringer spokesman said. Abbott Laboratories, which co-markets Mobic in the United States, said last month it expected U.S. sales of the drug to hit $1 billion in 2005. If you or a loved one has been injured by Mobic, Parker & Waichman, LLP will evaluate your case for free. Click here for a free, no obligation, case evaluation. Mobic (Meloxicam) From Wikipedia, the free encyclopedia. Meloxicam is a nonsteroidal anti-inflammatory drug used to relieve the symptoms of arthritis, primary dysmenorrhoea, pyrexia; and as an analgesic, especially where there is an inflammatory component. It is closely related to piroxicam.In Europe it is marketed under the names of Movalis, Melox, and Recoxa. Mechanism of action Meloxicam is an NSAID and, as such is a cyclooxygenase (COX) inhibitor. It is generally marketed under the name MOBIC. Meloxicam has been shown, especially at its low therapeutic dose, to selectivly inhibit COX-2 over COX-1. Adverse effects Meloxicam use can result in gastrointestinal toxicity, tinnitus, headache, and rash. The risk of adverse side effects is lower than with piroxicam, diclofenac, or naproxen. Although it does inhibit thromboxane A, it does not appear to do so at levels that would interfere with platelet function. Approval status Meloxicam is quite popular in Europe for treatment of rheumatoid arthritis. It has recently (as of 2004) been approved for use in treating osteoarthritis in the United States. If you or a loved one has been injured by Mobic, Parker & Waichman, LLP will evaluate your case for free. Click here for a free, no obligation, case evaluation.